4-(1-甲基-1H-吡唑-4-基)吡啶 | 870863-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(1-甲基-1H-吡唑-4-基)吡啶
• 英文名称: 4-(1-methyl-1H-pyrazol-4-yl)pyridine
• 英文别名: 4-(1-methylpyrazol-4-yl)pyridine
• CAS: 870863-00-6
• 化学式: C₉H₉N₃
• mdl: MFCD01936590
• 分子量: 159.191
• InChiKey: FJJQOGZWCRKCKM-UHFFFAOYSA-N

物化性质

• 沸点：
  306℃
• 密度：
  1.13
• 闪点：
  139℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  1-甲基-4-碘-吡唑 、 吡啶-4-硼酸 在 四(三苯基膦)钯 、 caesium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 0.17h， 以90%的产率得到4-(1-甲基-1H-吡唑-4-基)吡啶
  参考文献：
  名称：

  Efficient synthesis of 4-substituted pyrazole via microwave-promoted Suzuki cross-coupling reaction

  摘要：

  Pyrazoles and their derivatives are important heterocycles found in nature and present in numerous bioactive compounds. In contrast to 3 or 5-aryl pyrazole, the preparation of 4-aryl pyrazole is fairly rare. Utilizing microwave irradiation, the synthesis of 4-substituted-arylpyrazole via Suzuki cross-coupling has been developed with a wide range of substrates. The remarkable advantages of this method are mild reaction conditions, simple operation, high yield, and short reaction time. Product structures were identified by MS, H-1 NMR, C-13 NMR, and elemental analysis. (C) 2014 Qiong-You Wu and Guang-Fu Yang. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2014.03.013

文献信息

• Palladium‐Catalyzed Electrophilic Functionalization of Pyridine Derivatives through Phosphonium Salts
  作者：Yuan‐Yuan Che、Yanni Yue、Ling‐Zhi Lin、Bingbing Pei、Xuezu Deng、Chao Feng

  DOI：10.1002/anie.202006724

  日期：2020.9.14

  Herein, we report a highly efficient and practical method for pyridine‐derived heterobiaryl synthesis through palladium‐catalyzed electrophilic functionalization of easily available pyridine‐derived quaternary phosphonium salts. The nice generality of this reaction was goes beyond arylation, enabling facile incorporation of diverse carbon‐based fragments, including alkenyl, alkynyl, and also allyl

  本文中，我们报告了一种通过钯催化的易得的吡啶衍生的季phospho盐的亲电官能团合成吡啶衍生的杂二芳基化合物的高效实用方法。该反应的通用性超出了芳基化的范围，从而可以轻松地将各种碳基片段（包括烯基，炔基以及烯丙基片段）掺入吡啶核中。值得注意的是，银盐添加剂被发现对于成功实现这种转化至关重要，并且还描述了其作为金属转移介质的关键作用，该介质可确保吡啶基向钯中间体的平稳转移。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20100286126A1

  公开（公告）日：2010-11-11

  A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 and R 3 are as defined herein.

  化合物的公式（I）或其立体异构体或药用可接受的盐，以及它们的制备和用途作为药物，其中R1、R2和R3如本文所定义。
• [EN] N-HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 N-HÉTÉROCYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010019391A1

  公开（公告）日：2010-02-18

  The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的化合物，这些化合物是M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES
  申请人：Flynn Daniel L.

  公开号：US20080269254A1

  公开（公告）日：2008-10-30

  Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyctosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

  本发明的化合物在哺乳动物癌症的治疗中具有实用价值，特别是人类癌症，包括但不限于恶性黑色素瘤、胶质母细胞瘤、卵巢癌、胰腺癌、前列腺癌、肺癌、乳腺癌、肾癌、宫颈癌、原发肿瘤部位的转移、骨髓增生性疾病、白血病、乳头状甲状腺癌、非小细胞肺癌、间皮瘤、高嗜酸性综合症、胃肠道间质瘤、结肠癌、眼病，其特征为导致失明的过度增殖，包括各种视网膜病变、类风湿性关节炎、哮喘、慢性阻塞性肺病、肥大细胞增多症、肥大细胞白血病、由c-Abl激酶引起的疾病、其癌变形式、异常融合蛋白和多态形式，或由c-Kit激酶引起的疾病，其癌变形式、异常融合蛋白和多态形式。
• ORGANIC COMPOUNDS
  申请人：Fairhurst Robin Alec

  公开号：US20120004212A1

  公开（公告）日：2012-01-05

  A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 and R 3 are as defined herein.

  公式（I）的化合物或其立体异构体或药学上可接受的盐，以及它们的制备和用途作为药物，其中R1，R2和R3如此定义。